SWEDEPAD and BASIL-3 trials recommended to resume enrolment - Vascular News

SWEDEPAD and BASIL-3 trials recommended to resume enrolment  Vascular News

Investigators of SWEDEPAD have announced the conclusion of their safety committee analysis, which recommends the halted trials to resume.



Comments

Post a Comment

Popular posts from this blog

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease - Vascular Disease Management

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease    Vascular Disease Management First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease; Follows ...
Read more